Ireland
--:--IST
Recruiting Not applicable

Periodization Resistance Training on Quality of Life in Females With Hypothyroidism

NCT06757712 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-01-01
Last updated
2025-09-12

Condition(s) studied

Hypothyroidism

Investigational drug(s) / intervention(s)

non linear periodization exerciselinear periodization exercisemedical treatment

non linear periodization exercise: The non-linear periodized resistance training program follows a 12-week schedule with varying intensity levels across three training days per week. The intensity fluctuates between very light (VL), light (L), moderate (M), heavy (H), and very heavy (VH) workouts, distributed strategically throughout the week. Each training day implements different intensity levels, and an active rest day follows any workout session.

linear periodization exercise: The linear periodization exercise program spans 12 weeks with systematically varied training parameters. During weeks 1-2, participants perform 3 sets of 10 repetitions, followed by 3 sets of 8 repetitions in weeks 3-4. The program progresses to 4 sets of 6 repetitions in weeks 5-6, then 3 sets of 6 repetitions during weeks 7-8. The final phases consist of 4 sets of 4 repetitions in weeks 9-10, concluding with 3 sets of 4 repetitions in weeks 11-12. Training loads advance through autoregulatory progression, where participants progress at their individual pace under supervision. While sets and repetitions remain fixed within each phase, load progression is determined by performance in the final set of each exercise, ensuring safe and effective advancement.

medical treatment: The medical treatment will be received for 12 weeks.

Study summary

This study will be conducted to compare between the effect of nonlinear and linear periodized training on quality of life in females with hypothyroidism.

Eligibility

Sex
FEMALE
Min age
35 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Be controlled hypothyroidism (TSH level within 0.5 - 4.5 mU/L) * Be ranged from 35 to 45 years * Female patients * Body Mass Index 30-34.9 kg/m2 . * triglyceride-glucose (TyG) index \> 4.5 Exclusion Criteria: * history of pulmonary disease * Patients with uncontrolled coronary or cerebrovascular disease * Those who underwent musculoskeletal surgery within the previous year * Recent history of lower and upper limb fracture , hip and shoulder dislocation. * Cognitive impaired patients * Patients with history of epilepsy * Patients who participating in any other exercise program

Primary outcome measure(s)

  • Serum thyroid stimulating hormone (TSH) level — 12 weeks
    It will be measured by ELISA kits. This kit is an Enzyme Linked Immunosorbent Assay (ELISA). (Precheck bio, inc, @ EIA KIT, USA).
  • FreeT4 (thyroxine) level — 12 weeks
    It will be measured by ELISA kits. This kit is an Enzyme Linked Immunosorbent Assay (ELISA). (Precheck bio, inc, @ EIA KIT, USA).
  • Health related Quality of life questionnaire — 12 weeks
    The Health related Quality of life will be assessed using short form 12 (SF-12), which uses only 12 questions to measure functional health and well being from the patient's perspective. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Trial sites (1)

FacilityCityRegionStatus
Suez University Suez Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06757712 on ClinicalTrials.gov ↗ ← All trials in Egypt